ABT
NYSE · Health Care
Abbott Laboratories
$91.05
-1.66 (-1.79%)
ABT News21 articles
Pfizer Shares Slip as CFO Departure Rattles Investors; 2026 Outlook Intact
Pfizer shares fell 2.7% to $25.21 after CFO Dave Denton said he will leave in August, reigniting investor concerns over succession and obesity-drug competition.
Medtronic Stock Edges Up on Earnings Beat, Tariff Warning Looms
Medtronic shares slipped 0.32% to $81.67 Friday after a post-earnings rally, as strong Q4 revenue growth and a dividend hike were offset by a $250 million tariff hit and profit guidance below consensus.
Medtronic Surges on Strong Heart-Device Sales, But 2027 Profit Outlook Caps Gains
Medtronic shares surged 5.1% after beating Q4 estimates, fueled by 78% cardiac ablation growth, but gains were capped by a weak 2027 profit outlook and tariff concerns.
Boston Scientific Tumbles 16% on Watchman Slowdown; Focus Shifts to Monday's Reaction
Boston Scientific shares fell 16.4% last week after CEO Michael Mahoney warned of declining Watchman usage and flat growth through Q3. Wells Fargo downgraded the stock and slashed its price target.
Medtronic Stock Drops 6% Ahead of Earnings Report
Medtronic shares fell 6.1% last week to $73.81 ahead of its fiscal Q4 earnings on June 3. Options imply a 4.1% move. The company recently agreed to buy SPR Therapeutics for $650 million.
Boston Scientific Plunges to Two-Year Low on Watchman Slowdown
Boston Scientific shares fell 10% to a two-year low after CEO Michael Mahoney flagged slower use of its Watchman heart implant, raising growth concerns.
Medtronic Hovers Near 52-Week Low as Market Awaits Earnings
Medtronic shares closed at $76.15, near their 52-week low, as broader market weakness weighed ahead of the company's June 3 earnings report.
Tech Stocks Drive Market Gains Amid Ceasefire Relief and Earnings Strength
U.S. stocks climbed Wednesday, with the Nasdaq leading gains as technology shares rallied following an extended Iran ceasefire and a wave of corporate earnings. Oil prices remained elevated near $100 a barrel.
S&P 500, Nasdaq Scale New Peaks on Earnings Strength, Ceasefire Hopes
Major U.S. equity indices climbed to record levels Thursday, driven by strong corporate results and hopes for a de-escalation in Middle East tensions, though rising oil prices and mixed economic data introduced notes of caution.
Hologic Completes $17.3B Private Equity Buyout, Almeida Named CEO
Blackstone and TPG have closed their $17.3 billion acquisition of Hologic, taking the company private. José Almeida succeeds Steve MacMillan as CEO, with former shareholders receiving $76 per share plus potential earnout.
Hologic CEO to Depart as $18.3B Private Equity Acquisition Nears Completion
Hologic announced CEO Steve MacMillan will step down once the company's $18.3 billion acquisition by Blackstone and TPG finalizes, expected around April 7. The deal will take the women's health technology firm private.
SCHD ETF Sees Strong Q1 Inflows After Dividend Hike and Portfolio Overhaul
The Schwab U.S. Dividend Equity ETF (SCHD) reported a 3.3% dividend increase and $4 billion in first-quarter inflows following a significant portfolio reshuffle that boosted healthcare and tech exposure while reducing energy holdings.
SCHD ETF Boosts Healthcare in Rebalance as Dividend Fund Inflows Surge
The Schwab U.S. Dividend Equity ETF (SCHD) increased its healthcare allocation to 18.5% during its yearly portfolio update, adding Abbott Laboratories and UnitedHealth Group. The fund gathered nearly $4 billion in the first quarter as investors poured a total of $24.1 billion into U.S. dividend-focused funds, marking the strongest quarterly start since 2022.
SCHD ETF Gains Investor Attention Following Annual Rebalance and Dividend Payout
The Schwab U.S. Dividend Equity ETF (SCHD) is drawing renewed interest following its annual portfolio rebalance and a recent dividend distribution. The fund's strategic shift and income profile are being highlighted as key attractions for investors.
Danaher Shares Slip Ahead of Holiday, Traders Eye PCE Data
Danaher shares fell in extended trading Friday, closing near $212.58. The dip precedes a market holiday, with attention shifting to next week's key inflation report.
Boston Scientific Stock Rebounds on Positive Farapulse Data, CHAMPION-AF Trial Looms
Boston Scientific shares recovered slightly after a recent sell-off, supported by new long-term data for its Farapulse ablation system. Investor focus now shifts to the upcoming CHAMPION-AF trial results expected in late March.
Boston Scientific Shares Extend Decline Amid Electrophysiology Concerns
Boston Scientific stock fell 2.6% in Monday trading, continuing last week's selloff as investors scrutinize the company's heart-rhythm device segment and Watchman demand.
Abbott Shares Gain on Insider Purchase and Positive Cardiac Device Data
Abbott Laboratories stock rose 1.6% Friday following a director's $1.09 million share purchase and new clinical data for its heart rhythm devices presented at a medical symposium.
Abbott Faces Regulatory Scrutiny on Libre Sensors as Insider Buying and New AFib Data Emerge
Abbott shares rose 1.6% to $110.83 Friday but remain 21.5% below their 52-week high. The FDA updated a Class I recall for FreeStyle Libre 3 sensors, citing 860 serious injuries and seven deaths, while an insider purchased 10,000 shares.
AbbVie Shares Gain 2% to Close Near $223 Amid Earnings Volatility, Credit Upgrade
AbbVie stock rose 2% Friday, ending a turbulent week marked by earnings scrutiny and a Moody's credit rating upgrade. Investors remain focused on Skyrizi and Rinvoq growth amid competitive pressures.
J&J Stock Rises as Court Disqualifies Talc Litigation Firm, AFib Device Data Released
Johnson & Johnson shares gained 0.9% following a New Jersey appeals court decision to remove Beasley Allen from state talc cases and the release of early 12-month data for its investigational AFib device.